
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
over 18 years ago
Current Management of Glaucoma and the Need for Complete Therapyover 18 years ago
History of Neuroprotection and Rationale as a Therapy for Glaucomaover 18 years ago
Managed Care and the Impact of Glaucoma





